Latest Conference

Previous research has suggested an association between bacteria from the Bovis group streptococci, Clostridium septicum and colorectal cancer

Investigators have hypothesized that scarlet fever transmission is driven by pediatric cases with symptomatic disease.

A new survey found that parents in Spain were the most supportive of vaccinations when compared with their counterparts in 4 other European countries.

Whole genome sequencing revealed little overlap between MDROs found in pets and pet owners.

A poster presented at CROI 2020 examined rates of TB screening among people living with HIV in PEPFAR supported countries.

Patients facing HIV stigma may encounter difficulties with retention in care.

George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.

An antibody gene delivered by a harmless virus produced anti-HIV antibodies for a sustained period.

Higher HIV incidence is associated with higher viral burden, according to results from the PopART trial presented at CROI 2020.

A new study examining the reasons for suboptimal PrEP use among MSM was presented at CROI 2020.

Data from clinical and preclinical studies on the use of the investigational HIV-1 capsid inhibitor GS-6207 were presented via 3 posters at CROI 2020.

Unaddressed mental health challenges among youth living with HIV complicate antiretroviral therapy (ART) adherence, leading to high mortality and lower rates of viral suppression among this population.

Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.

There was a statistically significant difference in renal safety which favored F/TAF over F/TDF at Week 96.

The rate of viral suppression among US youth aged 13 to 24 with HIV (YWH) hovers between 12 and 26%, representing an important clinical and public health challenge.

The time is now to put in place comprehensive action plans now to monitor, detect, and respond to treatment failure on dolutegravir.

The abstract authors report that both HIV viral load in plasma and proviral HIV DNA in CD4 cells have remained below levels of detection for up to 30 months.

Reducing barriers to care is paramount for people living with HIV and one such barrier in some countries, such as Zimbabwe, is high treatment loads that affect health system efficiency.

Women living with HIV who are on an antiretroviral therapy regimen of dolutegravir experienced persistently higher weight postpartum compared with women on efavirenz in Botswana.

“There are structural drivers that are impeding prevention and treatment among people who inject drugs,” Strathdee said in an interview with Contagion®.

For African men living with HIV who are not virally suppressed, community-based antiretroviral therapy (ART) significantly increased viral suppression compared with clinic-based ART.

New Week 96 data from the FLAIR study indicate that once-monthly injections of cabotegravir and rilpivirine remains non-inferior and safe when compared with the daily, oral 3-drug regimen of ABC/DTG/3TC.

A team of investigators hypothesized that prevalent syphilis infection in women with and without HIV may be a way to identify individuals who are at an elevated risk of a stillbirth over time.

Despite the high level of knowledge surrounding immediate initiation of ART, the practice is not yet the standard of care across clinics in NYC.

An international team of investigators shares 48-week results from ATLAS-2M, which tested out every other month dosing of the intramuscular injection compared with monthly dosing.

Investigators conducted 2 studies on intravenously administered GS-9722, 1 in HIV-negative participants and 1 in virally suppressed people with HIV.

A generic pre-exposure prophylaxis (PrEP) option would greatly expand coverage among vulnerable populations and may well be the most cost-effective and safe option.

Patients who had OUD and sepsis were found to be younger and healthier than patients without OUD.